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In the current theme issue, we have asked three expert teams
to address the question of the reliability of guidelines in the
prevention and treatment of infectious diseases. Reliable
guidelines should provide unbiased recommendations based
on the best available evidence, allowing local application in
different settings. Recommendations go a step further than a
simple review of the evidence, as they may incorporate
preferences, considerations of cost-effectiveness, applicability
in special populations, and temporal and local particularities.
Local and temporal considerations are particularly important
in infectious diseases, as the epidemiology of pathogens and
their resistance to antibiotics change with time and from place
to place.
The three reviews have adopted three distinct viewpoints in
assessing guidelines. The ﬁrst is based on a survey conducted
expressly for this review in 2013, and reports on National
Immunization Technical Advisory Groups (NITAGs) in differ-
ent European states: their composition, the procedures
followed, and the criteria considered for decision-making
regarding immunization policies [1]. A second review under-
takes the systematic grading of the methodology of 20
published guidelines on the treatment of pneumonia and
urinary tract infections (UTIs), according to the Appraisal of
Guidelines for Research & Evaluation II (AGREE-II) criteria [2].
The third review compares recommendations on the man-
agement of invasive fungal infections of the European Confer-
ence on Infection in Leukaemia, the European Society of
Clinical Microbiology and Infectious Diseases, and the Infec-
tious Diseases Society of America, examining their grading
systems, the actual recommendations, and their grading [3].
These three reviews, from their respective angles, have
identiﬁed several weaknesses and areas in need of develop-
ment and improvement.
There is a clear advantage in harmonizing efforts to review
the evidence on which guidelines are based, as noted in the
review on immunization practices in Europe [1]. Multiple
efforts across the globe to summarize evidence on vaccine
efﬁcacy or any other topic are redundant. Systematic reviews
of the literature, obtaining published and unpublished clinical
trials [4], critically appraising primary trials and grading the
evidence should be the standard. Guideline panels need to
deﬁne the scope of their guideline, the conditions addressed,
relevant outcomes, and relevant patient subgroups of interest.
Guideline developers might then need to commission a review
when one does not exist, to ask a review group to update an
existing review, or address outcomes, interventions or sub-
groups that have not been included in the original review.
Frameworks for such collaborations should be encouraged.
The Cochrane Infectious Diseases Group interacts with
various guideline development panels in the WHO in this
way, thus improving the efﬁciency of both systematic review
and guideline development processes [5,6]. This leaves guide-
line panels the complex process of reviewing the evidence with
respect to local and contemporary epidemiology and resis-
tance patterns, addressing local applicability, and accounting
for stakeholders’ preferences or values, the availability of
vaccines and drugs, and the evaluation of costs and cost-effec-
tiveness. Thus, different national guideline committees might
use the same evidence summary differently. Examples include:
guidelines on the use of pneumococcal vaccine or rotavirus
vaccine in one country but not another, based on differences in
epidemiology; a national policy to vaccinate adolescent girls
against human papilloma virus, based on local preferences or
values [7]; guidelines for the treatment of UTIs that recom-
mend mecillinam in Denmark, but quinolones in the USA,
based on local resistance patterns and drug availability; and
guidelines for the treatment of fungal infections that recom-
mend conventional amphotericin B in some settings but
liposomal amphotericin B in others, based on economic
considerations. Recommendations should be made even when
evidence is lacking, but in this case we expect to know when a
recommendation is based on expert opinion.
The process of devising guidelines for prevention or
treatment should start by deﬁning the interventions, outcomes
and populations of relevance for the condition addressed. Data
on these should then be sought from the existing evidence:
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systematic reviews, clinical trials, and, when these are lacking,
observational studies. Guideline developers should be careful
not to reverse this logical process by summarizing interven-
tions and outcomes reported in clinical trials before, or instead
of, deﬁning clinically and policy-relevant outcome parameters.
For example, in the review on management of fungal infections,
a difference was observed with regard to the recommendation
for the use of amphotericin B in the empirical treatment of
candidaemia in non-neutropenic patients. In the Infectious
Diseases Society of America guidelines, conventional ampho-
tericin B received a class A recommendation (i.e. ‘good
evidence to support a recommendation for use’) [8], whereas,
in the European Society of Clinical Microbiology and Infectious
Diseases guidelines, it was classiﬁed as D (‘supports a
recommendation against use’) [9]. The explanation for the
class D recommendation is ‘Substantial renal and infu-
sion-related toxicity’. If guideline developers were to deﬁne
in advance the goal of empirical treatment (e.g. reducing
mortality among patients with candidaemia), it is likely that
both guidelines would result in a similar recommendation
(based on the results for mortality in the clinical trials).
For both antifungal and antibacterial agents, there are two
levels of ‘beneﬁt’ to be considered when a recommendation is
devised: in vitro coverage and efﬁcacy. It is easy enough to
consider coverage in decision-making, but more difﬁcult to
incorporate efﬁcacy data. In the review of the guidelines for
the treatment of bacterial infections, the authors found very
little discussion on the effectiveness of recommended anti-
biotics with regard to the relevant outcomes [2]. Rather, the
more evidence-based guidelines compiled interventions that
were tested and proved to be non-inferior or superior to a
comparator, and based their recommendations mainly on
coverage. Clinicians expect guideline developers to consider
comparative efﬁcacy data when selecting between classes of
antibiotics or speciﬁc antibiotics; unfortunately, this is rarely
presented in current guidelines.
Recommendations in evidence-based guidelines are classi-
ﬁed with a level of evidence and a level of recommendation.
There is a misunderstanding in some guidelines about the
difference between the two, with the grading of recommen-
dation appearing completely parallel with the evidence grading.
Furthermore, there is a lack of uniformity in scoring systems.
This is confusing to end-users, and makes the comparison
between guidelines difﬁcult. Finally, as noted in the review
examining the methodological quality of guidelines on the
treatment of bacterial infections, evidence appraisal by guide-
line panels is currently mostly limited to the assessment of
study design. The assessment of the internal validity of study
reports is very limited, and is not incorporated in the
recommendation grading. In this respect, the GRADE working
group is an important initiative to harmonize grading of the
quality of evidence and strength of recommendations [10]. The
GRADE system addresses study design, but also the risk of bias
in randomized controlled trials, inconsistency, indirectness,
imprecision, publication bias, effect size, confounding, and
dose–response relationship, and proposes a uniform grading
system. Summary-of-ﬁndings tables based on the GRADE
classiﬁcation are currently included in Cochrane systematic
reviews. They have yet to be adopted in current guidelines.
Public and patient consultation was a weak point identiﬁed
in the reviews on immunization policies and treatment of
bacterial infections [1,2]. This was especially surprising when
guidelines on the treatment of UTIs were examined, as the
treatment of uncomplicated UTIs is aimed mainly at symptom
improvement. It would therefore seem self-evident that
women should be consulted when outcomes are prioritized.
In fact, none of the current guidelines on the treatment of UTIs
described a process of public or patient consultation. Similarly,
when the activities of NITAGs in Europe were examined, lay
members were represented in a single NITAG among the 22
surveyed. As an example, the current need for and degree of
public involvement in national vaccination programmes was
demonstrated in Israel, where the recent re-emergence of
wild-type poliovirus triggered national recommendations to
vaccinate all children who were not previously vaccinated with
the live oral polio vaccine [11]. This resulted in a huge public
debate about the safety and effectiveness of the polio vaccine,
subsequently evolving to a debate about childhood vaccination
in general. Barring the public from decision-making regarding
national vaccination programmes is likely to thwart attempts at
the eradication of certain infectious diseases.
Last, but not least, there is the issue of managing the
unavoidable problem of conﬂict of interest. There is always a
concern that undue (e.g. corporate) inﬂuences may affect
decision-making in guideline development groups. Although
strict application of evidence-based methods in guideline
development minimizes these inﬂuences, there will always
remain questions where the evidence is insufﬁcient or requires
interpretation that allows personal opinion to inﬂuence
decisions. We have not found sufﬁcient attention to this
problem in current guidelines and NITAGs. Conﬂict of interest
statements are not universally provided. When they were, we
did not ﬁnd a description of how these were dealt with. Both
as lay persons and as physicians, we would like persons with
commercial conﬂicts of interests to be excluded from
decision-making on topics related to their conﬂict, at the very
least.
Clinicians appreciate guidelines, as they form the basis for
their own decision-making, and standardize and simplify clinical
practice. Guidelines published on the worldwide web are
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currently available at the touch of a ﬁnger. With increasing use
and accessibility, guideline developers need to consider their
great impact. Equally, journal editors and societies need to
consider carefully the quality of published guidelines. Recently,
the Dutch Q fever Consensus Group proposed guidelines for
the diagnosis of chronic Q-fever [12]. At the time of writing,
these had already been cited 15 times, much more frequently
than Raoult’s commentary pointing at conceptual and actual
inaccuracies in this consensus statement [13]. In recent years,
guidelines in infectious diseases have come a long way towards
evidence-based medicine, as well as clear and uniform
presentation. There remains, however, a considerable way to
go, in the direction of improving their quality and transparency.
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